GlaxoSmithKline said on Monday it had applied for U.S. approval for its experimental multiple myeloma drug that showed meaningful response in nearly a third of patients, setting up a battle against Johnson & Johnson and Genmab's Darzalex.
from Reuters: Health News https://ift.tt/38Jwnvj
via
IFTTT